hrp0095rfc2.1 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Muscle function in XLH - Two year prospective observation of paediatric patients before and after treatment initiation with burosumab

Rehberg Mirko , Heistermann Johanna , Neuburg Lisa , Schönau Eckhard , Hoyer-Kuhn Heike-Katharina , Semler Oliver

X-linked hypophosphatemia (XLH, MIM 307800) is a rare hereditary disorder of bone metabolism characterized by growth impairment, leading to bone deformities and short stature and beside others to muscle function deficits. XLH is caused by defect of endopeptidase PHEX leading to high levels of FGF-23 and thereby renal phosphate wasting. While conventional treatment includes substitution of phosphate and 1-25 OH-Vitamin D, now a treatment with a FGF-23 antibody (burosumab) is av...

hrp0095rfc2.2 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Single-center analysis of quality of life in patients with X-linked hypophosphatemia (XLH)

Raimann Adalbert , Haufler Florentina , Ertl Diana-Alexandra , Haeusler Gabriele

Background: X-linked hypophosphatemia (XLH) is a rare metabolic bone disease which is caused by inactivating mutations in Phosphate-regulating neutral endopeptidase, X-linked (PHEX). Due to dysregulation of Fibroblast growth factor 23 (FGF-23), increased systemic levels of FGF-23 lead to chronic renal phosphate wasting and to impaired activation of 25OH-Vitamin D (25OHD). As a result, patients suffer from multiple musculoskeletal symptoms such as long bone def...

hrp0095rfc2.3 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

The European Registries for Rare Bone and Mineral Conditions: Registering New Cases of Paediatric Rare Bone and Mineral Conditions Using an Electronic Reporting Tool

Luisa Priego Zurita Ana , Bryce Jillian , Alves Inês , Boarini Manila , Grasemann Corinna , Högler Wolfgang , Kassim Javaid M , Linglart Agnès , Mohnike Klaus , Mordenti Marina , Mortier Geert , Roos Marco , Sangiorgi Luca , Skarberg Rebecca , Soucek Ondrej , Faisal Ahmed S , Appelman-Dijkstra Natasha M

Introduction: The European Registries for Rare Bone and Mineral Conditions (EuRR-Bone) are closely linked to the European Reference Networks on Rare Bone Diseases (ERN BOND) and Rare Endocrine Conditions (Endo-ERN) and with its registry EuRRECa. It is open to all professionals involved in the care of individuals with rare bone and mineral conditions. EuRR-Bone offers an electronic reporting tool (e-REC) for capturing newly encountered cases without collecting ...

hrp0095rfc2.4 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Dysosteosclerosis is also caused by null mutations of TNFRSF11A

Kırkgöz Tarık , Ozkan Behzat , Acar Sezer , Hazan Filiz , Ikegawa Shiro , Guo Long

Dysosteosclerosis (DOS) is a rare form of dense bone disease and, short stature, recurrent fractures, optic atrophy, cranial nerve palsy, developmental delay, flattened fingernails, skin related complications, and failure of tooth eruption are the characteristic features of the disease (MIM %224300). Irregular osteosclerosis, flattened diffusely dense vertebral bodies, sclerotic skull, radiolucent sub-metaphyseal portions of the long tubular bones with sclerotic diaphysis are ...

hrp0095rfc2.5 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Bone biopsy histomorphometric features of vertebral changes in sickle cell disease.

Sakka Sophia , Nadar Ruchi , Inusa Baba , Cocca Alessandra , Santos Rui , Cheung Moira

Background: Vertebral changes such as biconcave end plate depressions are well described in children with sickle cell disease (SCD). However, as vertebral height reductions are a marker of osteoporosis in children, we aimed to determine whether these could present underlying osteoporosis, by performing transiliac bone biopsies in two patients.Case 1: A 13-year-old female with SCD, presented with back pain. She had delaye...

hrp0095rfc2.6 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Genetic liability and late adverse musculoskeletal, metabolic and mental health effects in a cohort of survivors of childhood acute lymphoblastic leukemia – a PETALE study

Nadeau Geneviève , Yazdanpanah Mojgan , Yazdanpanah Nahid , Krajinovic Maja , Alos Nathalie , Manousaki Despoina

Objectives: Survivors of childhood acute lymphoblastic leukemia (cALL) present elevated fracture rates compared to the general population. A polygenic risk score for estimated bone mineral density (BMD), named gSOS, validated to predict the risk of adult osteoporotic fracture, has been previously associated with significant fracture risk in childhood. We hypothesized that gSOS could be associated with long-term, bone health-related mobidities in survivors of c...

hrp0095rfc3.1 | Early Life and Multisystem Endocrinology | ESPE2022

Brain Magnetic Resonance Imaging Changes in Childhood and its possible correlation with Unrecognised Early Life Hypoglycaemia

Ramya Gokul Pon , Banerjee Indraneel , Ramsden Katie , Worth Chris , Worthington Sarah , Salomon Estebanez Maria

Introduction: The neonatal threshold for hypoglycaemia is debatable and makes its treatment challenging. Neonatal hypoglycaemia can be transient and yet pose a significant risk of neuroglycopaenia, especially with severe and recurrent hypoglycaemia in Congenital Hyperinsulinism. Untreated hypoglycaemia induced cerebral injury can be identified by magnetic resonance (MR) brain scan changes affecting cerebral white matter, occipital lobes and posterior parietote...

hrp0095rfc3.2 | Early Life and Multisystem Endocrinology | ESPE2022

The Hypoglycaemia Error Grid: a UK-wide Consensus on CGM Accuracy Assessment in Hypoglycaemia due to Congenital Hyperinsulinism

Worth Chris , J Dunne Mark , Salomon-Estebanez Maria , Harper Simon , W Nutter Paul , Dastamani Antonia , Senniappan Senthil , Banerjee Indraneel

Background and Objective: Continuous Glucose Monitoring (CGM) is gaining in popularity for patients with paediatric hypoglycaemia disorders such as Congenital Hyperinsulinism (CHI), but no standard measures of accuracy or associated clinical risk are available. A small number of studies have shown suboptimal accuracy of CGM in CHI but assessments have been inconsistent, incomplete and offer no measure of clinical application. Error grids that categorise clinic...

hrp0095rfc3.3 | Early Life and Multisystem Endocrinology | ESPE2022

Analysis of A Series of Italian Apeced Patients with Autoimmune Liver Disease and Enteropathies

Fierabracci Alessandra , Cappa Marco , Pietrobattista Andrea , Felicia Faienza Maria , Capalbo Donatella , Valenzise Mariella , Lampasona Vito , Pagliarosi Olivia , Carbone Elena , Carolina Salerno Maria , Betterle Corrado

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED, OMIM240300) is a rare monogenic disease due to biallelic mutations in the Autoimmune Regulator (AIRE) gene. This encodes for a thymus-enriched transcription factor responsible for central immune tolerance. Classic diagnostic criteria are the presence of two of main symptoms of chronic mucocutaneous candidiasis (CMC), hypoparathyroidism (HP) and Addison’s disease (AD). Non-endocrine autoimmun...

hrp0095rfc3.4 | Early Life and Multisystem Endocrinology | ESPE2022

Immunophenotype and proinflammatory cytokines in ROHHAD(NET) patients compared to age- and sex-matched obese patients

Angelelli Alessia , Morandi Fabio , Prigione Ignazia , Fava Daniela , Napoli Flavia , Maghnie Mohamad

Background: ROHHAD(NET) syndrome has been proposed as an acquired neuroimmunological dysfunction. Aim of the study is to compare the phenotype of lymphocyte subpopulations in patients vs controls and to evaluate the plasma levels of pro-inflammatory cytokines/chemokines in ROHHADNET syndrome.Patients and Methods: We included 14 patients (9F;5M), selected by clinical criteria, matched with 11 controls with simple obesity ...